J9033 HCPCS code: Injection, bendamustine hydrochloride, not otherwise specified, 1 mg
J9033 is the HCPCS Level II code for injection, bendamustine hydrochloride, not otherwise specified, 1 mg. In 2024 Medicare paid an average of $5.34 per service for J9033 across 637,557 services. Its Medicare coverage code is C (Carrier judgment): Coverage is decided by the Medicare contractor (MAC) case by case. The NCCI unit limit is 300 per day on outpatient hospital claims. Medicare volume rose 44% from 2022 to 2024 (442,766 to 637,557 services). In 2024, about 654 clinicians billed Medicare for J9033 for 617 beneficiaries; Florida, California, Tennessee accounted for 58% of services.
Code details
| Field | Value |
|---|---|
| Section | J codes — Drugs administered other than oral method |
| Coverage code | C — Carrier judgment |
| Pricing indicator | 51 — Drug or biological (priced per ASP/average sales price rules) |
| BETOS category | O1D — Chemotherapy |
| Added | 2009-01-01 |
| Last action effective | 2026-10-01 |
Who bills J9033 (2024)
| Measure | Value |
|---|---|
| Clinicians billing (by place of service) | 654 |
| Medicare beneficiaries | 617 |
| States with claims | 15 |
| Share of services in top 3 states (Florida, California, Tennessee) | 58% |
Counts only. Supplier and clinician names, contact lists and state-by-state detail are in Caduvo.
Medicare utilization for J9033, 2022–2024
| Year | Services | Beneficiaries | Avg. allowed | Avg. paid |
|---|---|---|---|---|
| 2022 | 442,766 | 463 | $18.12 | $14.48 |
| 2023 | 686,050 | 637 | $12.73 | $10.14 |
| 2024 | 637,557 | 617 | $6.71 | $5.34 |
States with the most J9033 services (2024)
| State | Services | Avg. paid |
|---|---|---|
| Florida | 187,804 | $5.73 |
| California | 87,421 | $5.11 |
| Tennessee | 49,846 | $5.34 |
| Indiana | 35,051 | $5.09 |
| Michigan | 33,077 | $6.05 |
NCCI unit limits (MUE)
| Claim type | Max units per day | Rationale |
|---|---|---|
| outpatient hospital claims | 300 | Prescribing Information |
| practitioner claims | 300 | Prescribing Information |
What changed for J9033
- October 2026: Descriptor revised (Was: Injection, bendamustine hydrochloride, 1 mg)
- 2026-10-01: Last CMS action: long description changed
- 2009-01-01: J9033 added to HCPCS Level II
- Next scheduled CMS quarterly update (HCPCS and DMEPOS fee schedule): 2027-01-01
Frequently asked questions
What is HCPCS code J9033?
J9033 is the HCPCS Level II code for injection, bendamustine hydrochloride, not otherwise specified, 1 mg. Short descriptor: "Inj, bendamustine (nos) 1mg".
How much does Medicare pay for J9033?
In 2024, the average Medicare payment was $5.34 per service (average allowed $6.71).
Does Medicare cover J9033?
Coverage code C — Carrier judgment. Coverage is decided by the Medicare contractor (MAC) case by case.
How many units of J9033 can be billed per day?
300 on outpatient hospital claims; 300 on practitioner claims (NCCI medically unlikely edits).
Related J90 codes
- J9000 — Injection, doxorubicin hydrochloride, 10 mg
- J9003 — Leuprolide injectable (camcevi etm), 1 mg
- J9010 — Injection, alemtuzumab, 10 mg
- J9011 — Injection, datopotamab deruxtecan-dlnk, 1 mg
- J9015 — Injection, aldesleukin, per single use vial
- J9017 — Injection, arsenic trioxide, 1 mg
- J9019 — Injection, asparaginase (erwinaze), 1,000 iu
- J9020 — Injection, asparaginase, not otherwise specified, 10,000 units
- J9021 — Injection, asparaginase, recombinant, (rylaze), 0.1 mg
- J9022 — Injection, atezolizumab, 10 mg
- J9023 — Injection, avelumab, 10 mg
- J9024 — Injection, atezolizumab, 5 mg and hyaluronidase-tqjs
Building a device that would bill under a code like this? Caduvo matches a device description to HCPCS/CPT codes, Medicare coverage and payment, and the FDA pathway in one report.
Next steps
- Run a reimbursement report for a device billed under J9033
- Watch J9033 for fee, coverage and descriptor changes
- Build a full Medicare revenue model for J9033
Compiled by Caduvo from public CMS (Medicare) records, HCPCS release October 2026. Fees are Medicare allowables, not commercial rates. Not reviewed or endorsed by CMS. Not billing or legal advice. Report an error. Data and corrections policy.